Intellia Therapeutics to Present at September Investor Healthcare Conferences
September 01 2016 - 7:00AM
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome
editing company focused on the development of potentially curative
therapeutics using CRISPR/Cas9 technology, announced that CEO and
Founder Nessan Bermingham, Ph.D., will present at key September
investor healthcare conferences, including the 2016 Wells Fargo
Healthcare Conference, the Morgan Stanley Global Healthcare
Conference and the Leerink Rare Disease & IO Roundtable Series.
Details of the upcoming presentations are as follows:
Wednesday, September 7th 2016 Wells
Fargo Healthcare ConferenceLocation: The Westin
Waterfront, BostonPresentation Time: 3:30-4:00 PM ET
Tuesday, September 13th2016 Morgan
Stanley Global Healthcare ConferenceLocation: Grand Hyatt
New York, New YorkPresentation Time: 5:15-5:40 PM ET
Wednesday, September 28thLeerink Rare
Disease & IO Roundtable Series, 2016Location: Lotte
New York Palace, New YorkPresentation Time: 2:05-2:30 PM ET
Individuals may access the presentations for each conference via
live webcast on the Intellia website at
www.intelliatx.com under "Events & Presentations" in the
"Investor Relations" section. A replay of the webcast will be
available on this site for 90 days following the live event.
About Intellia Therapeutics
Intellia Therapeutics is a leading genome editing company,
focused on the development of proprietary, potentially curative
therapeutics using the CRISPR/Cas9 system. Intellia believes the
CRISPR/Cas9 technology has the potential to transform medicine by
permanently editing disease-associated genes in the human body with
a single treatment course. Our combination of deep scientific,
technical and clinical development experience, along with our
leading intellectual property portfolio, puts us in a unique
position to unlock broad therapeutic applications of the
CRISPR/Cas9 technology and create a new class of therapeutic
products. Learn more about Intellia Therapeutics and CRISPR/Cas9 at
intelliatx.com; Follow us on Twitter @intelliatweets.
Media Contact:
Jennifer Mound Smoter
Chief External Affairs & Communications Officer
+1 224-804-4462
jenn.smoter@intelliatx.com
Investor Contacts:
John Graziano
Trout Group
+1 646-378-2942
jgraziano@troutgroup.com
Chad Rubin
Trout Group
+1 646-378-2947
crubin@troutgroup.com
Intellia Therapeutics (NASDAQ:NTLA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Intellia Therapeutics (NASDAQ:NTLA)
Historical Stock Chart
From Apr 2023 to Apr 2024